FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3027175095> ?p ?o ?g. }

• W3027175095 endingPage "100353" @default.
• W3027175095 startingPage "100353" @default.
• W3027175095 abstract "Women living with HIV (WLWH) are at higher risk of acquisition and progression of human papillomavirus (HPV) infection. Evidence on effect of HPV vaccination in this population is limited.This phase IV randomized controlled observer-blind study assessed immunogenicity and safety of two HPV vaccines (AS04-HPV-16/18 vs. 4vHPV) given in WLWH (stage 1) and HIV- females aged 15-25 years. Co-primary endpoints were to demonstrate, in WLWH subjects, non-inferiority (and if demonstrated, superiority) of AS04-HPV-16/18 vs. 4vHPV for HPV-16 and HPV-18 by pseudovirion-based neutralization assay (PBNA) at month 7 and safety. Non-inferiority criteria was lower limit (LL) of the 95% confidence interval (CI) of the GMT ratio AS04-HPV-16/18/4vHPV above 0.5, in the according to protocol population. NCT01031069.Among 873 subjects recruited between 26-Oct-2010 and 14-May-2015, 546 were randomized (1:1) and received at least one vaccine dose (total vaccinated cohort, TVC): 257 were WLWH (129 AS04-HPV-16/18; 128 4vHPV) and 289 were subjects without HIV (144 AS04-HPV-16/18; 145 4vHPV). Baseline CD4 cell count in WLWH was at least 350 cells/mm3.At month 7, AS04-HPV-16/18 showed immunological superiority to 4vHPV in WLWH. Neutralizing anti-HPV-16 and HPV-18 antibody GMTs were 2·74 (95% CI: 1·83; 4·11) and 7·44 (95% CI: 4·79; 11·54) fold higher in AS04-HPV-16/18 vs. 4vHPV (LL of the GMT ratio >1 in TVC, p<0·0001), respectively. Similar results were observed by ELISA up to month 24.Solicited local and general symptoms were in line with product labels. The number of reported serious adverse events (SAEs) was balanced throughout the study.Both vaccines showed an acceptable safety profile in all subjects. Despite the absence of an immunological correlate of protection for HPV, differences in immune responses elicited by the vaccines especially for HPV-18 may translate into longer lasting or more robust protection against cervical cancer with the AS04-HPV-16/18 vaccine in WLWH." @default.
• W3027175095 created "2020-05-29" @default.
• W3027175095 creator A5002075684 @default.
• W3027175095 creator A5006200330 @default.
• W3027175095 creator A5008813104 @default.
• W3027175095 creator A5010353641 @default.
• W3027175095 creator A5019142277 @default.
• W3027175095 creator A5019152388 @default.
• W3027175095 creator A5022916073 @default.
• W3027175095 creator A5024245378 @default.
• W3027175095 creator A5024931884 @default.
• W3027175095 creator A5029719318 @default.
• W3027175095 creator A5032814621 @default.
• W3027175095 creator A5034519528 @default.
• W3027175095 creator A5035765905 @default.
• W3027175095 creator A5036140670 @default.
• W3027175095 creator A5039860812 @default.
• W3027175095 creator A5042629578 @default.
• W3027175095 creator A5043933161 @default.
• W3027175095 creator A5051707431 @default.
• W3027175095 creator A5054642897 @default.
• W3027175095 creator A5056119251 @default.
• W3027175095 creator A5056231807 @default.
• W3027175095 creator A5059940446 @default.
• W3027175095 creator A5071753660 @default.
• W3027175095 creator A5073643745 @default.
• W3027175095 creator A5081087840 @default.
• W3027175095 creator A5081758373 @default.
• W3027175095 creator A5084608261 @default.
• W3027175095 creator A5089391672 @default.
• W3027175095 creator A5091152768 @default.
• W3027175095 date "2020-06-01" @default.
• W3027175095 modified "2023-10-11" @default.
• W3027175095 title "Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 years: A phase IV randomized comparative study" @default.
• W3027175095 cites W1987350137 @default.
• W3027175095 cites W1993945172 @default.
• W3027175095 cites W2001429203 @default.
• W3027175095 cites W2006287503 @default.
• W3027175095 cites W2070371366 @default.
• W3027175095 cites W2081047239 @default.
• W3027175095 cites W2086404290 @default.
• W3027175095 cites W2100812202 @default.
• W3027175095 cites W2101196984 @default.
• W3027175095 cites W2108018524 @default.
• W3027175095 cites W2114391710 @default.
• W3027175095 cites W2119545652 @default.
• W3027175095 cites W2127058706 @default.
• W3027175095 cites W2139736159 @default.
• W3027175095 cites W2155851362 @default.
• W3027175095 cites W2174946562 @default.
• W3027175095 cites W2590070418 @default.
• W3027175095 cites W2757798274 @default.
• W3027175095 cites W2769565077 @default.
• W3027175095 cites W2769604813 @default.
• W3027175095 cites W2834937974 @default.
• W3027175095 cites W2914111421 @default.
• W3027175095 doi "https://doi.org/10.1016/j.eclinm.2020.100353" @default.
• W3027175095 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7329699" @default.
• W3027175095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32639485" @default.
• W3027175095 hasPublicationYear "2020" @default.
• W3027175095 type Work @default.
• W3027175095 sameAs 3027175095 @default.
• W3027175095 citedByCount "9" @default.
• W3027175095 countsByYear W30271750952020 @default.
• W3027175095 countsByYear W30271750952021 @default.
• W3027175095 countsByYear W30271750952022 @default.
• W3027175095 countsByYear W30271750952023 @default.
• W3027175095 crossrefType "journal-article" @default.
• W3027175095 hasAuthorship W3027175095A5002075684 @default.
• W3027175095 hasAuthorship W3027175095A5006200330 @default.
• W3027175095 hasAuthorship W3027175095A5008813104 @default.
• W3027175095 hasAuthorship W3027175095A5010353641 @default.
• W3027175095 hasAuthorship W3027175095A5019142277 @default.
• W3027175095 hasAuthorship W3027175095A5019152388 @default.
• W3027175095 hasAuthorship W3027175095A5022916073 @default.
• W3027175095 hasAuthorship W3027175095A5024245378 @default.
• W3027175095 hasAuthorship W3027175095A5024931884 @default.
• W3027175095 hasAuthorship W3027175095A5029719318 @default.
• W3027175095 hasAuthorship W3027175095A5032814621 @default.
• W3027175095 hasAuthorship W3027175095A5034519528 @default.
• W3027175095 hasAuthorship W3027175095A5035765905 @default.
• W3027175095 hasAuthorship W3027175095A5036140670 @default.
• W3027175095 hasAuthorship W3027175095A5039860812 @default.
• W3027175095 hasAuthorship W3027175095A5042629578 @default.
• W3027175095 hasAuthorship W3027175095A5043933161 @default.
• W3027175095 hasAuthorship W3027175095A5051707431 @default.
• W3027175095 hasAuthorship W3027175095A5054642897 @default.
• W3027175095 hasAuthorship W3027175095A5056119251 @default.
• W3027175095 hasAuthorship W3027175095A5056231807 @default.
• W3027175095 hasAuthorship W3027175095A5059940446 @default.
• W3027175095 hasAuthorship W3027175095A5071753660 @default.
• W3027175095 hasAuthorship W3027175095A5073643745 @default.
• W3027175095 hasAuthorship W3027175095A5081087840 @default.
• W3027175095 hasAuthorship W3027175095A5081758373 @default.
• W3027175095 hasAuthorship W3027175095A5084608261 @default.
• W3027175095 hasAuthorship W3027175095A5089391672 @default.
• W3027175095 hasAuthorship W3027175095A5091152768 @default.
• W3027175095 hasBestOaLocation W30271750951 @default.

• next